Novo Nordisk Wegovy Launch Shows Early Demand
Novo Nordisk Wegovy saw early U.S. retail uptake and a U.K. higher-dose approval, signaling fresh demand and dosing shifts that matter for traders.
KEY TAKEAWAYS
- Oral Wegovy recorded 3,071 U.S. retail prescriptions in its first four days post-launch.
- Those retail prescriptions accounted for 1.3% of total Wegovy prescriptions.
- U.K. regulators approved a 7.2 mg weekly injectable dose after Phase 3b showed about 21.0% average weight loss.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk launched Wegovy in the U.S. on January 5, 2026, recording brisk early retail uptake. On January 16, 2026, U.K. regulators approved a 7.2 mg weekly injectable dose, altering near-term demand and dosing expectations for investors.
Early U.S. Uptake
In the first four days after the U.S. launch, retail pharmacies dispensed 3,071 prescriptions for the oral semaglutide tablet, excluding online fills. These retail prescriptions accounted for 1.3% of total Wegovy prescriptions. The oral version became available following FDA clearance in late December 2025. Analysts consider this early retail tally an initial signal of demand for oral GLP-1 treatments, a class of drugs that mimic a hormone regulating appetite and blood sugar.
U.K. Approval and Higher Dose
The U.K. Medicines and Healthcare products Regulatory Agency approved a 7.2 mg weekly injectable dose for adults with a body-mass index of 30 kg/m² or greater, raising the previous maximum dose of 2.4 mg. A Phase 3b study showed the higher dose led to an average body-weight reduction of about 21%, a few percentage points more than the standard dose. Novo Nordisk is seeking U.S. approval for this elevated injectable dose, though no timeline has been disclosed.
Pricing and Access
GoodRx lists the oral semaglutide tablet at roughly $149 to $150 per month, with availability at more than 70,000 pharmacies nationwide. This combination of modest cash pricing and broad pharmacy reach could influence early patient access and adoption as payers and clinicians evaluate treatment options.
